Physician profile
Nancy A Harris
NPI 1144259532
$5,129.00
in general payments reported to CMS, 2019-2025
36 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $391 · 2021: $428 · 2022: $1,116 · 2023: $653 · 2024: $1,020 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.74 | 2019-2023 | |
| Minerva Surgical, INC | $704.08 | 2019-2021 | |
| Coopersurgical, INC. | $484.74 | 2019-2024 | Paragard T 380a |
| Hologic Sales and Service, LLC | $480.78 | 2020-2024 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Organon LLC | $413.43 | 2021-2024 | Nexplanon |
| Gynesonics, INC. | $190.91 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $169.46 | 2019-2024 | |
| Roche Diagnostics Corporation | $147.30 | 2020-2023 | Cobas 4800 Ct/Ng Test V2.0 |
| Sumitomo Pharma America, INC. | $137.48 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $137.43 | 2023-2024 | Veozah |
| Becton, Dickinson and Company | $129.83 | 2025 | Bd Onclarity |
| Avanos Medical | $125.66 | 2019 | |
| Therapeuticsmd, INC. | $116.16 | 2019-2021 | |
| Millicent US INC | $107.30 | 2019-2024 | Femring, Intrarosa |
| Exeltis, USA INC. | $106.57 | 2019-2024 | Slynd |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $105.44 | 2023 | Apretude |
| Pfizer INC. | $91.36 | 2020-2024 | |
| Evofem Biosciences, INC. | $78.17 | 2020-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $77.34 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.41 | 2019-2020 | |
| Avion Pharmaceuticals | $56.67 | 2019-2022 | |
| Myovant Sciences INC. | $54.84 | 2022 | |
| Amag Pharmaceuticals, INC. | $43.54 | 2019 | |
| Mylan Pharmaceuticals INC. | $42.96 | 2020-2021 | |
| Agile Therapeutics, INC. | $42.68 | 2021-2023 | Twirla |
| Channel Medsystems, INC. | $37.31 | 2023 | |
| Baxter Healthcare | $34.57 | 2024 | Perclot |
| Duchesnay USA Incorporated | $29.74 | 2019 | |
| Daiichi Sankyo INC. | $28.17 | 2022 | |
| Allergan, INC. | $27.67 | 2019-2020 | |
| Medline Industries LP | $18.25 | 2023 | |
| Medtronic, INC. | $18.11 | 2022 | |
| Optumhealth Care Solutions, LLC | $16.69 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
| Amgen INC. | $15.29 | 2024 | Prolia, Evenity |
| Boston Scientific Corporation | $15.26 | 2019 | |
| Lupin INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.